Weight Watchers Integrates with LillyDirect to Expand Obesity Care

WW International (NASDAQ:WW) has integrated its Weight Watchers Med+ program with Eli Lilly's (NYSE:LLY) LillyDirect healthcare platform, broadening access to clinical weight management services for patients using or considering prescription obesity treatments.

Partnership Details

The collaboration connects LillyDirect users—who can access telemedicine and obesity medication prescriptions—with Weight Watchers' program, which combines GLP-1 drugs (such as tirzepatide and semaglutide) with behavioral, nutritional, and lifestyle support.

Context

The move comes amid explosive growth in the obesity treatment market, as companies like WW seek to strengthen their position through partnerships with major pharmaceutical firms. It also reflects a shift toward integrated care models that combine drug therapy with behavioral support.

What It Means for Investors

The partnership offers WW a chance to expand its user base by tapping into LillyDirect's patient pool, while Eli Lilly benefits from providing comprehensive support to its customers. However, financial terms were not disclosed, making it difficult to assess the direct revenue impact for either company.